VHL regulates angiogenesis and a loss of this gene incancer cells results in increased production of growth factors like VEGF [7].Alternatively, receptor tyrosine kinase inhibitors like Sorafenib that blocksignaling through affected pathways are now approved or in clinical trials for thetreatment of advanced renal cancers [8]. The gene discussed is VHL; the disease is renal carcinoma.